Faeth Therapeutics, Inc（FTH）の株式分析FTHFaeth Therapeutics, Inc

Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib. It operates in the Healthcare sector.

Faeth Therapeutics is a good buy right now due to its current price of $17.08, which is significantly below analyst price targets, with Guggenheim setting a target of $70. The stock's RSI is at 20.185, indicating it is oversold and may be due for a rebound. However, the main risk is the negative earnings trend, with a recent EPS of -2.84, which reflects ongoing losses that could impact investor sentiment.